Skip to main content

Table 1 Pts receiving locoregional Tx at first progression.

From: Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

Locoregional Tx # pts # pts achieving ≥1yr
disease control
CNS, surgery and/or RT 9/80 (11%) 5/9 (56%)
Non-CNS, surgery 11/80 (14%) 8/11 (73%)
Non-CNS, RT 6/80 (8%) 3/6 (50%)
Ablation 2/80 (3%) 1/2 (50%)